Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
181 Results Found
AHA 340B Advocacy Alliance Bulletin - October 17, 2025
Senate HELP Committee to hold hearing on 340B program
Fact Sheet: 340B Drug Pricing Program: Fact vs Fiction
For nearly 30 years, the 340B Drug Pricing Program has provided financial help to safety-net hospitals to manage rising prescription drug costs. Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to qualifying health care organizations that care for many uninsured and low-income patients.
Contact Your Senators Prior to Oct. 23 Senate HELP Committee Hearing on 340B
The U.S. Senate Committee on Health, Education, Labor and Pensions Oct. 23 will hold a hearing titled, “The 340B Program: Examining Its Growth and Impact on Patients.”
Fact Sheet: The 340B Drug Pricing Program
Learn what the HHS 340B Drug Pricing Program is and what 340B hospitals are. The program allows 340B hospitals to stretch limited federal resources to reduce the price of outpatient pharmaceuticals for patients by providing 340B drug pricing discounts and expand health services to the patients and communities they serve.
AHA 340B Advocacy Alliance - October 9, 2025
In 2022, tax-exempt hospitals participating in the 340B Drug Pricing Program provided nearly $100 billion in total benefits to their communities, according to a new AHA report.
340B Advocacy Alliance Bulletin - September 30, 2025
In a letter responding to HRSA’s information collection request regarding the expected costs of its 340B Rebate Model Pilot Program, the AHA said 340B hospitals indicated that the operational costs associated with the rebate model could range from $150,000 to over $500,000 per hospital.
AHA Letter to HRSA Re: The 340B Rebate Model Pilot Program
AHA comments on the Health Resources and Services Administration’s (HRSA) information collection request (ICR) regarding the expected costs of its 340B Rebate Model Pilot Program.
AHA 340B Advocacy Alliance Bulletin - September 24, 2025
The U.S. District Court for the District of Maine today issued an order denying preliminary injunctions requested by AbbVie and Novartis in legal challenges against the state’s law protecting 340B pricing for contract pharmacy arrangements.
AHA 340B Advocacy Alliance Bulletin - September 16, 2025
AHA 340B Advocacy Alliance Bulletin - September 16, 2025.
AHA Details Legislative Priorities for Congressional Leaders
Hospitals and health systems are experiencing significant financial pressures that challenge their ability to provide 24/7 care for the patients and communities they serve. As Congress begins to focus on its end-of-the-year work, America’s hospitals and health systems respectfully request that you consider the following priorities.